| 000 | 00889 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250513094719.0 | ||
| 264 | 0 | _c19961009 | |
| 008 | 199610s 0 0 spa d | ||
| 022 | _a0025-7753 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVílchez, J J | |
| 245 | 0 | 0 |
_a[3,4-diaminopyridine in the treatment of myasthenic syndromes. Practical aspects]. _h[electronic resource] |
| 260 |
_bMedicina clinica _cJan 1996 |
||
| 300 |
_a37-8 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 |
_a4-Aminopyridine _xadministration & dosage |
| 650 | 0 | 4 | _aAmifampridine |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLambert-Eaton Myasthenic Syndrome _xdrug therapy |
| 650 | 0 | 4 |
_aMyasthenia Gravis _xdrug therapy |
| 650 | 0 | 4 | _aPotassium Channels |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aCasanova, B | |
| 700 | 1 | _aMonte, E | |
| 773 | 0 |
_tMedicina clinica _gvol. 106 _gno. 1 _gp. 37-8 |
|
| 999 |
_c8747546 _d8747546 |
||